JP2008538586A - 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド） - Google Patents

酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド） Download PDF

Info

Publication number
JP2008538586A
JP2008538586A JP2008507992A JP2008507992A JP2008538586A JP 2008538586 A JP2008538586 A JP 2008538586A JP 2008507992 A JP2008507992 A JP 2008507992A JP 2008507992 A JP2008507992 A JP 2008507992A JP 2008538586 A JP2008538586 A JP 2008538586A
Authority
JP
Japan
Prior art keywords
nac amide
mixture
compound
nac
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008507992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538586A5 (enExample
Inventor
グレン エー． ゴールドスタイン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2008538586A publication Critical patent/JP2008538586A/ja
Publication of JP2008538586A5 publication Critical patent/JP2008538586A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00—Formation of filaments, threads, or the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
JP2008507992A 2005-04-21 2006-04-21 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド） Pending JP2008538586A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67356105P 2005-04-21 2005-04-21
US70596705P 2005-08-05 2005-08-05
PCT/US2006/015548 WO2006116353A2 (en) 2005-04-21 2006-04-21 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress

Publications (2)

Publication Number Publication Date
JP2008538586A true JP2008538586A (ja) 2008-10-30
JP2008538586A5 JP2008538586A5 (enExample) 2009-07-09

Family

ID=37215387

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507992A Pending JP2008538586A (ja) 2005-04-21 2006-04-21 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）

Country Status (9)

Country Link
US (3) US20090234011A1 (enExample)
EP (1) EP1877044A4 (enExample)
JP (1) JP2008538586A (enExample)
KR (1) KR20080028357A (enExample)
AU (1) AU2006238888A1 (enExample)
CA (1) CA2606053A1 (enExample)
IL (1) IL186684A0 (enExample)
RU (1) RU2007143040A (enExample)
WO (1) WO2006116353A2 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011088829A (ja) * 2009-10-20 2011-05-06 Chube Univ 発癌毒性の評価方法及び発癌予防・治療剤
JP2012102041A (ja) * 2010-11-09 2012-05-31 Maruzen Pharmaceut Co Ltd 抗酸化剤及び抗炎症剤
JP2015527999A (ja) * 2012-07-10 2015-09-24 エックスピーディ・ホールディングス・リミテッド・ライアビリティ・カンパニーＸＰＤ Ｈｏｌｄｉｎｇｓ ＬＬＣ 安定化された多機能酸化防止化合物およびその使用方法
JP2016523975A (ja) * 2013-07-10 2016-08-12 グレン・エー・ゴールドスタイン 穿通性頭部外傷の処置におけるｎ−アセチルシステインアミドの使用
JP2017534673A (ja) * 2014-09-15 2017-11-24 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
JP2018503689A (ja) * 2015-01-27 2018-02-08 フローレンゲイル・エル・エル・シー 治癒性局所用組成物
JP2019501226A (ja) * 2016-01-11 2019-01-17 プレッドファルマ・アーベー 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤
JP2021502323A (ja) * 2017-11-09 2021-01-28 ナキュイティ ファーマシューティカルズ， インク．Ｎａｃｕｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 重水素濃縮ｎ−アセチルシステインアミド（ｄ−ｎａｃａ，ｄｅｕｔｅｒｉｕｍ−ｅｎｒｉｃｈｅｄ ｎ−ａｃｅｔｙｌｃｙｓｔｅｉｎｅ ａｍｉｄｅ）及び（２ｒ，２ｒ’）−３，３’−ジスルファンジイルビス（２−アセトアミドプロパンアミド）（ｄｉｎａｃａ）を作製する、並びに酸化ストレスが関与する疾患を治療するためにｄ−ｎａｃａ及びｄｉｎａｃａを使用する方法
JP2021193119A (ja) * 2014-11-07 2021-12-23 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
JP2022518174A (ja) * 2019-01-11 2022-03-14 ナキュイティ ファーマシューティカルズ， インク． 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
JP2023511369A (ja) * 2020-01-24 2023-03-17 ナキュイティ ファーマシューティカルズ， インク． 酸化ストレスの疾患及び傷害の治療のためのプロドラッグ
US12245998B2 (en) 2019-01-11 2025-03-11 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis
US12667548B2 (en) 2014-11-07 2026-06-30 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312103T1 (de) 1999-01-25 2005-12-15 Nat Jewish Med & Res Center Substituierte porphyrine und deren therapeutische verwendungen
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
CA2606053A1 (en) 2005-04-21 2006-11-02 Glenn Goldstein N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
JP2009525948A (ja) * 2005-12-20 2009-07-16 シラメッド・インコーポレーテッド 高親油性スルフヒドリル化合物の製薬組成物及び使用方法
US20100099762A1 (en) * 2006-10-23 2010-04-22 The Mental Health Research Institute Of Victoria Combination therapy
US20080146579A1 (en) * 2006-12-15 2008-06-19 N.V. Nutricia Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore
US9095578B2 (en) * 2007-01-12 2015-08-04 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
CN102088965B (zh) * 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
DK2300003T3 (da) 2008-05-23 2014-05-26 Nat Jewish Health Forbindelser til anvendelse i behandling af skade forbundet med eksponering for en alkylerende art
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
TWI535440B (zh) 2009-10-26 2016-06-01 Ｌｇ生命科學有限公司 包括吲哚化合物之醫藥組成物
US9433596B2 (en) 2010-09-06 2016-09-06 Snu R&Db Foundation Pharmaceutical composition comprising N-acetyl-L-cysteine or its derivatives for treating anxiety disorder
FR2964967A1 (fr) 2010-09-17 2012-03-23 Exsymol Sa Peptidomimetiques derives de la methionine et leur utilisation dans la protection des mitochondries des cellules cutanees
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
WO2012106654A1 (en) 2011-02-04 2012-08-09 Hough Ear Institute Methods for treating brain injury
WO2013138744A1 (en) * 2012-03-16 2013-09-19 M. Alphabet 1, Llc Compositions for the treatment of skin disorders
US9605047B2 (en) * 2012-04-04 2017-03-28 The Brigham And Womens's Hospital, Inc. Compositions and methods for treating hypertension
WO2013163545A1 (en) * 2012-04-26 2013-10-31 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
EP3066089B1 (en) 2013-11-08 2019-11-06 Promentis Pharmaceuticals, Inc. Substituted n-acetyl-l-cysteine derivatives and related compounds
US20150209310A1 (en) * 2014-01-24 2015-07-30 Brighton Biotech, Inc. Naca for the treatment of chronic or low impact brain trauma
WO2015112724A1 (en) * 2014-01-24 2015-07-30 Brighton Biotech, Inc. Naca for the treatment of chronic or acute cognitive dysfunction
WO2015134166A2 (en) * 2014-02-12 2015-09-11 Goldstein Glenn A Use of n-acetylcysteine amide in the treatment of aquired immune deficiency syndrome and hiv infection
US11268964B2 (en) 2014-11-11 2022-03-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
WO2016197089A1 (en) * 2015-06-05 2016-12-08 Goldstein Glenn A Use of n-acetylcysteine amide in the treatment of acetaminophen overdose
CN109562098B (zh) * 2016-04-29 2023-04-21 奥菲瑞克斯股份有限公司 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂
US12662449B2 (en) 2017-09-20 2026-06-23 Nacuity Pharmaceuticals, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US11548851B2 (en) 2017-09-20 2023-01-10 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US11091433B2 (en) 2017-09-20 2021-08-17 Nacuity Pharmaceutials, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US20240368072A1 (en) * 2017-09-20 2024-11-07 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives
CA3079196C (en) 2017-09-20 2021-05-18 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US20240342118A1 (en) * 2017-09-20 2024-10-17 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives
US20240217927A1 (en) * 2017-11-09 2024-07-04 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US20190151271A1 (en) * 2017-11-21 2019-05-23 The Johns Hopkins University Compositions and methods for treatment of eye diseases
WO2019107913A1 (ko) * 2017-11-28 2019-06-06 주식회사 셀투인 실시간 글루타치온 측정을 통한 치료용 세포의 품질 향상 방법
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
US11497758B2 (en) 2018-11-15 2022-11-15 Samuel L. Shepherd Method of treating oxidative stress due to radiation exposure
AU2020206139A1 (en) 2019-01-11 2021-07-29 Nacuity Pharmaceuticals, Inc. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with N-acetylicysteine amide (NACA) or 2R,2R')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (diNACA)
CN109758581A (zh) * 2019-02-14 2019-05-17 上海市东方医院（同济大学附属东方医院） 一种抗氧化磁性氧化铁纳米颗粒及其制备方法
EP3984993A4 (en) * 2019-06-13 2023-07-19 Shanghai Kechow Pharma, Inc. USE OF AMINOTHIOL COMPOUNDS AS CEREBRAL NERVE OR HEART PROTECTIVE AGENTS
CA3165422A1 (en) 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders
WO2021252378A1 (en) * 2020-06-08 2021-12-16 Nacuity Pharmaceuticals, Inc. Prevention or treatment of covid-19
US20230263725A1 (en) * 2020-07-09 2023-08-24 Beyond Barriers Therapeutics, Inc. Intranasal administration of an antioxidant compound for treating coronavirus infection
IL300416A (en) * 2020-08-06 2023-04-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Oleylcysteine amide or its derivatives and their uses
EP3960168A1 (en) * 2020-08-28 2022-03-02 Université de Genève Compositions and methods comprising d-cysteine or a derivative thereof
CN112602724B (zh) * 2020-12-21 2021-09-24 上海汉今医疗科技有限公司 一种感染性医疗废物消毒液及其制备方法
AU2022204064A1 (en) 2021-07-16 2023-02-02 Samuel L. Shepherd Method of treating oxidative stress due to radiation exposure
CN115449065B (zh) * 2022-09-21 2023-09-22 中南大学湘雅医院 一种nac改性血液净化膜及其制备方法
WO2026015776A1 (en) * 2024-07-12 2026-01-15 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US6420429B1 (en) * 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5691380A (en) 1995-06-29 1997-11-25 The Procter & Gamble Company Stable n-acetylcysteine compositions and methods for treating human skin therewith
US5733535A (en) * 1995-10-25 1998-03-31 The Procter & Gamble Co. Topical compositions containing N-acetylcysteine and odor masking materials
US5962421A (en) * 1996-05-16 1999-10-05 Zambon, S.A. Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases
US5874468A (en) 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US6719969B1 (en) 1999-08-09 2004-04-13 The Regents Of The University Of Michigan Treatment of liver disease and injury with CXC chemokines
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US6623754B2 (en) * 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
AU2002323249A1 (en) * 2001-08-16 2003-03-03 Boyce Thompson Institute For Plant Research, Inc. Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof
US20060211628A1 (en) * 2002-08-02 2006-09-21 Daphne Atlas Treatment of multiple sclerosis with brain targeted anti oxidant compounds
WO2004095926A2 (en) * 2003-04-28 2004-11-11 Monsanto Technology, Llc Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield
CA2606053A1 (en) 2005-04-21 2006-11-02 Glenn Goldstein N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
WO2006132712A2 (en) 2005-04-21 2006-12-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for enhancing plant resistance and tolerance to environmental stress
EP1881840A4 (en) * 2005-04-21 2009-08-05 Glenn A Goldstein N-ACETYLCYSTEINAMIDE (NAC-AMID) FOR THE TREATMENT OF OXIDATIVE STRESS IN CONNECTION WITH BARRENESS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US6420429B1 (en) * 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011088829A (ja) * 2009-10-20 2011-05-06 Chube Univ 発癌毒性の評価方法及び発癌予防・治療剤
JP2012102041A (ja) * 2010-11-09 2012-05-31 Maruzen Pharmaceut Co Ltd 抗酸化剤及び抗炎症剤
JP2015527999A (ja) * 2012-07-10 2015-09-24 エックスピーディ・ホールディングス・リミテッド・ライアビリティ・カンパニーＸＰＤ Ｈｏｌｄｉｎｇｓ ＬＬＣ 安定化された多機能酸化防止化合物およびその使用方法
JP2016523975A (ja) * 2013-07-10 2016-08-12 グレン・エー・ゴールドスタイン 穿通性頭部外傷の処置におけるｎ−アセチルシステインアミドの使用
JP2017534673A (ja) * 2014-09-15 2017-11-24 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
JP2023169413A (ja) * 2014-09-15 2023-11-29 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
JP2021181473A (ja) * 2014-09-15 2021-11-25 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
JP2025160381A (ja) * 2014-11-07 2025-10-22 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｎ－アセチルシステインアミドによる網膜色素変性症の治療
US12472157B2 (en) 2014-11-07 2025-11-18 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa with n-acetylcysteine amide
JP2021193119A (ja) * 2014-11-07 2021-12-23 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
JP2023145734A (ja) * 2014-11-07 2023-10-11 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｎ－アセチルシステインアミドによる網膜色素変性症の治療
US12667548B2 (en) 2014-11-07 2026-06-30 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide
JP2018503689A (ja) * 2015-01-27 2018-02-08 フローレンゲイル・エル・エル・シー 治癒性局所用組成物
US11260060B2 (en) 2016-01-11 2022-03-01 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
JP7311267B2 (ja) 2016-01-11 2023-07-19 エゲティス・セラピューティクス・アーベー 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤
JP2022019973A (ja) * 2016-01-11 2022-01-27 エゲティス・セラピューティクス・アーベー 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤
JP7374163B2 (ja) 2016-01-11 2023-11-06 エゲティス・セラピューティクス・アーベー 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤
JP2019501226A (ja) * 2016-01-11 2019-01-17 プレッドファルマ・アーベー 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤
US12303516B2 (en) 2016-01-11 2025-05-20 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
JP2021502323A (ja) * 2017-11-09 2021-01-28 ナキュイティ ファーマシューティカルズ， インク．Ｎａｃｕｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 重水素濃縮ｎ−アセチルシステインアミド（ｄ−ｎａｃａ，ｄｅｕｔｅｒｉｕｍ−ｅｎｒｉｃｈｅｄ ｎ−ａｃｅｔｙｌｃｙｓｔｅｉｎｅ ａｍｉｄｅ）及び（２ｒ，２ｒ’）−３，３’−ジスルファンジイルビス（２−アセトアミドプロパンアミド）（ｄｉｎａｃａ）を作製する、並びに酸化ストレスが関与する疾患を治療するためにｄ−ｎａｃａ及びｄｉｎａｃａを使用する方法
JP2022518174A (ja) * 2019-01-11 2022-03-14 ナキュイティ ファーマシューティカルズ， インク． 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
JP2025069381A (ja) * 2019-01-11 2025-04-30 ナキュイティ ファーマシューティカルズ， インク． 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
US12245998B2 (en) 2019-01-11 2025-03-11 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis
US12458608B2 (en) 2019-01-11 2025-11-04 Nacuity Pharmaceuticals, Inc. N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
JP7631200B2 (ja) 2019-01-11 2025-02-18 ナキュイティ ファーマシューティカルズ， インク． 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
JP2023511369A (ja) * 2020-01-24 2023-03-17 ナキュイティ ファーマシューティカルズ， インク． 酸化ストレスの疾患及び傷害の治療のためのプロドラッグ

Also Published As

Publication number Publication date
US8354449B2 (en) 2013-01-15
WO2006116353A3 (en) 2007-06-28
WO2006116353A2 (en) 2006-11-02
US20100137441A1 (en) 2010-06-03
EP1877044A2 (en) 2008-01-16
KR20080028357A (ko) 2008-03-31
WO2006116353A8 (en) 2008-03-13
US8937099B2 (en) 2015-01-20
IL186684A0 (en) 2008-02-09
AU2006238888A1 (en) 2006-11-02
EP1877044A4 (en) 2009-09-02
CA2606053A1 (en) 2006-11-02
US20100120920A1 (en) 2010-05-13
RU2007143040A (ru) 2009-05-27
US20090234011A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
US8937099B2 (en) N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US10869846B2 (en) N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress
US8652518B2 (en) Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
Tekwani et al. 8-Aminoquinolines: future role as antiprotozoal drugs
US8871971B2 (en) Protection of normal cells
US6444221B1 (en) Methods of treating chronic inflammatory diseases using carbonyl trapping agents
JP2021193119A (ja) Ｎ−アセチルシステインアミドによる網膜色素変性症の治療
AU674330B2 (en) Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
Singh et al. Modulation of autoimmune diseases by nitric oxide
WO2011044230A2 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
US20090069428A1 (en) Catalytic antioxidants and methods of use
JP2022518174A (ja) 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
JP2015078185A (ja) Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法
KR20010083064A (ko) 디티오카르바메이트의 디술피드 유도체를 사용한 치료방법 및 이에 유용한 조성물
JP2001507696A (ja) グルタチオンの医薬製剤およびその投与方法
EP2696864A1 (en) Therapeutic compounds
CN101232877A (zh) 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺）
KR20220155271A (ko) 산화 스트레스의 질환 및 손상의 치료를 위한 전구약물
JPS58206524A (ja) 抗腫瘍剤
CN111989097A (zh) 用于预防或治疗急性辐射综合征的组合物
EP4487698A1 (en) A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
RU2807600C1 (ru) Антиоксидантный препарат для животных на основе водного раствора фуллерена С60, ресвератрола и альфа-липоевой кислоты
PT98593A (pt) Metodo para estimular a producao de superoxidos num mamifero utilizando tioete-res fenolicos
HK40129888A (zh) 含有芝麻素类化合物及阿魏酸或其盐的组合物
EP1596845A1 (fr) Utilisation therapeutique de glycerols acyles et de leurs analogues azotes et sulfures

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120713